Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics for severe respiratory diseases, with Cystic Fibrosis (CF) as the first target indication. Our development efforts are based on novel peptides that reduce the airway surface density of epithelial sodium channels (ENaC) via ligand-mediated internalization. This mechanism has a robust and durable effect on enhancing airway and mucus hydration to promote mucociliary clearance. We believe the mechanism of our investigational peptides has the potential to provide disease-modification for the dehydration associated lung disease that is a feature of CF, as well as having utility in multiple other pulmonary and non-pulmonary indications. Spyryx’s lead program, SPX-101, has successfully completed a Phase 1 safety study in healthy volunteers and is now being tested in a multinational Phase 2 study in individuals living with CF. The Phase 2, entitled "Hydration for Optimal Pulmonary Effectiveness" or HOPE-1, is a 28-day, placebo-controlled study intended to establish treatment proof of concept independent of CFTR mutation (www.clinicaltrials.gov/NCT03229252). This study has initiated recruitment in select sites in Canada and Western Europe. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.